GlassScriptPhysician profile
Joy A Anderson
NPI 1396920658
$36,468.03
in general payments reported to CMS, 2019-2025
18 companies · $719 in 2025
The $719 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.59 · 2020: $44.14 · 2021: $192 · 2022: $2,983 · 2023: $457 · 2024: $32K · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $31K · Food and Beverage: $1,997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $31,200.00 |
| Food and Beverage | $1,997.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $31,212.59 | 2024 | |
| Acera Surgical, INC. | $2,619.48 | 2022 | |
| Kerecis Limited | $781.21 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Organogenesis INC. | $396.07 | 2019-2025 | Puraply, Simplimax, Via Matrix |
| Smith+Nephew, INC. | $347.51 | 2020-2025 | Grafix Pl, Collagenase Santyl |
| Paratek Pharmaceuticals, INC. | $221.39 | 2022-2025 | Nuzyra |
| Aroa Biosurgery Incorporated | $170.61 | 2023 | |
| Averitas Pharma INC. | $139.96 | 2023-2025 | Qutenza |
| Mimedx Group, INC. | $125.78 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $97.82 | 2025 | |
| Horizon Therapeutics Plc | $91.73 | 2020-2021 | |
| Bioventus LLC | $84.12 | 2021-2023 | Exogen Ultrasound Bone Healing System |
| Triad Life Sciences INC. | $47.52 | 2022 | |
| Progenacare Global, LLC | $39.04 | 2023-2024 | |
| Biowound Solutions, INC. | $29.04 | 2025 | Bio-Connekt |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $24.99 | 2019 | |
| Cashflow Solutions, LLC | $20.45 | 2024 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Nabriva Therapeutics, Plc | $18.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.